유전자형 1형 만성 C형 간염 환자에서 혈청 인터페론감마유도단백질-10의 의미

초록

Background/Aims: Recent studies have shown that serum interferon γ-inducible protein-10 (IP-10) concentration decreased afterpegylated interferon and ribavirin therapy, and was associated with a sustained virologic response (SVR). The aim of this study wasto investigate the clinical significance of the pretreatment IP-10 level and change in serum IP-10 level between 1 month before andafter treatment and its association with various virologic responses in patients having chronic hepatitis C (CHC) with genotype 1undergoing pegylated interferon and ribavirin therapy. Methods: Thirty-six patients having CHC with genotype I undergoing pegylated interferon and ribavirin therapy who had availablestored sera 1 month before and after treatment were enrolled retrospectively. Serum IP-10 levels were measured by ELISA.Serum HCV RNA was measured by RT-PCR (detection limit<50 IU/mL). Results: The mean age of patients (n=36; 21 men) was 53.5 years, and the mean of pretreatment HCV RNA levels was 5.7 log10IU/mL. The serum IP-10 level at 1 month after treatment significantly decreased from 432.2 to 306.5 pg/mL (p=0.033). The rate ofrapid virologic response (RVR), early virologic response (EVR), end-of-treatment response (ETR), and SVR were 58%, 83%, 74%,and 57%, respectively. No significant difference in pretreatment IP-10 levels was observed between the patients with (RVR, EVR,ETR, and SVR) and without various virologic responses (p>0.05). The change in serum IP-10 between 1 month before and aftertreatment had no clinical meaning based on various virologic responses (p>0.05). Conclusions: The level of pretreatment IP-10 and change in IP-10 level between 1 month before and after treatment were not predictivefactors of a SVR. Additional large-scale studies to determine the SVR-predicting role of serum IP-10 levels in patients withCHC are needed. (Korean J Med 79:652-660, 2010)

키워드